Stenocare A/S
CSE:STENO
Stenocare A/S
Cash from Operating Activities
Stenocare A/S
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Stenocare A/S
CSE:STENO
|
Cash from Operating Activities
-kr7.1m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Novo Nordisk A/S
CSE:NOVO B
|
Cash from Operating Activities
kr131.2B
|
CAGR 3-Years
25%
|
CAGR 5-Years
23%
|
CAGR 10-Years
15%
|
|
|
H Lundbeck A/S
CSE:HLUN A
|
Cash from Operating Activities
kr3.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ALK-Abello A/S
CSE:ALK B
|
Cash from Operating Activities
kr1.3B
|
CAGR 3-Years
45%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
Stenocare A/S
Glance View
Stenocare A/S engages in the cultivation, manufacture, and distribution of medical cannabis products. The Company’s business model has two divisions: Import and wholesale of finished medical cannabis products for Danish patients, as well as Operate own cultivation- and production facility in Denmark to produce finished cannabis products for Danish and European patients. The firm distributes its products through pharmacies and hospitals. Stenocare's head office is located in Randers, Denmark.
See Also
What is Stenocare A/S's Cash from Operating Activities?
Cash from Operating Activities
-7.1m
DKK
Based on the financial report for Dec 31, 2024, Stenocare A/S's Cash from Operating Activities amounts to -7.1m DKK.
What is Stenocare A/S's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-23%
Over the last year, the Cash from Operating Activities growth was 29%. The average annual Cash from Operating Activities growth rates for Stenocare A/S have been 19% over the past three years , -23% over the past five years .
You don't have any saved screeners yet